{
    "nctId": "NCT04547907",
    "briefTitle": "A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer",
    "officialTitle": "Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer,HER2-positive",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 688,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: 18-70 years;\n2. Clinical T2-T4d, or T1c with axillary lymph node positivity;\n3. Histopathologically confirmed HER2-positive invasive breast cancer; Note: HER2 positivity was determined by immunohistochemical (IHC) staining of 3+ or, if IHC 2+, by HER2 gene amplification as demonstrated by fluorescence in situ hybridization (FISH) assay\uff1b\n4. Have clinically measurable lesions: Measurable lesions shown on ultrasound, mammography, or MR (optional) within 1 month before randomization;\n5. No chemotherapy contraindications detected by organ and bone marrow function tests within 1 month before chemotherapy:\n\n   1. Neutrophil count absolute value \u22672.0\u00d7109/L;\n   2. Hemoglobin \u2267 100g/L;\n   3. Platelet count \u2267100\u00d7109/L;\n   4. Total bilirubin \\<1.5 ULN (upper limit of normal);\n   5. Creatinine \\< 1.5\u00d7ULN\n   6. AST/ALT \\< 1.5\u00d7ULN;\n6. Cardiac ultrasound: Left ventricular ejection fraction (LVEF \u2265 55%);\n7. Reproductive age women, negative serum pregnancy test within 14 days before randomization;\n8. ECOG score 0 or 1;\n9. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Stage IV (metastatic) breast cancer;\n2. Bilateral breast cancer;\n3. Patients who have received chemotherapy, endocrine therapy, targeted therapy, or radiotherapy for this disease;\n4. Patients with a second primary malignancy, except for adequately treated skin cancer;\n5. Major non-breast cancer-related surgical procedures within the past 4 weeks before enrollment, or patients have not fully recovered from such surgical procedures;\n6. Severe heart disease or conditions that do not allow participation in the study, including but not limited to the following:\n\n   1. History of heart failure or systolic dysfunction (LVEF \\< 50%);\n   2. High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \\> 100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-grade atrioventricular conduction blocks (i.e., Mobitz II second-degree atrioventricular block or third-degree atrioventricular block);\n   3. Angina pectoris requiring anti-anginal drug therapy;\n   4. Clinically significant valvular heart disease;\n   5. ECG showing a transmural myocardial infarction;\n   6. Uncontrolled hypertension (systolic blood pressure \\> 180 mmHg and/or diastolic blood pressure \\> 100 mmHg);\n7. Due to severe and uncontrolled other medical conditions, the investigator considers chemotherapy to be contraindicated;\n8. Known history of allergy to any component of the study drugs; patients with a history of immune deficiency diseases, including HIV positivity, or patients with other acquired or congenital immune deficiency diseases, or a history of organ transplantation.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}